One obstacle in deciphering the role of BCATm in cancer progression and its therapeutic applications is that BCATm is constitutively expressed in all organs, except hepatocytes, while BCATc is expressed primarily in the central nervous system, immune, and cancer cells.1,21,22 Nevertheless, recent reports have suggested that BCATm is required for tumour growth in non-small cell lung carcinoma (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and gliomas.15,23,24. Here, BCAT2 is linked to glioma.